Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Фаза 2
Идёт, набор закрыт
NCT06502977
| Заболевание | Extensive Stage Small Cell Lung Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Amgen |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 32 участн. |
|---|
| Вмешательство | Tarlatamab |
|---|
| Дата начала | 27.08.2024 |
|---|
| Дата завершения | 28.03.2025 |
|---|
| Публикация результатов | 15.04.2026 |
|---|
Кратко
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off · percentage of participants
| Tarlatamab | 38.7 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.